There is some controversy regarding the optimum duration of tocolysis. This retrospective multicentre study was performed to evaluate whether long-term (> 2 days) tocolysis is effective in treating threatened premature labour. A total of 1147 eligible patients were grouped according to whether or not tocolytics were given, and according to route of administration and whether or not ritodrine (the standard tocolytic regimen in Japan) or other tocolytic was given. They were then further stratified into three subgroups, using the Baumgarten and Gruber tocolysis index (TI), to assess the efficacy of tocolysis treatment according to the risk of premature labour. Prolongation of gestation was significantly longer in patients treated with tocolytics for > 2 days compared with the unmedicated, bed-rest group. In women receiving tocolysis, the mean duration of prolonged gestation was 2.2 times longer in the intermediate-risk TI group and 3.1 times longer in the high-risk TI group compared with the unmedicated group. In the patients who received tocolysis, IV ritodrine was used in 86% of cases and was considered safe and effective for prolonging gestation in cases of threatened premature labour.
Introduction
The recent global increase in pre-term delivery is believed to be due to a greater use of assisted-reproductive technologies and a higher proportion of pregnant women of advanced age. 1, 2 Premature labour is one of the most frequently occurring disorders during gestation and is the primary cause of neonatal death: 85% of neonatal deaths due to disorders other than deformity are caused by prematurity at birth. 3 There are also longterm issues to consider with prematurity, including a higher incidence of complications such as cerebral palsy, mental retardation and retinopathy in affected infants. Furthermore, the costs of intensive care that premature neonates require can impose a serious economic burden: Jones et al. 4 reported that neonatal intensive care unit (NICU) expenses for newborns delivered at 34 weeks' gestation were over seven times higher than those for newborns who did not require specific treatment and that they could be reduced to a statistically significant degree with every additional week of gestation. 4
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Although a decrease in premature delivery rates seems highly desirable from medical and socio-economic perspectives, as yet there is no globally or locally established standard treatment for threatened premature labour. In addition, there is some controversy regarding the optimum duration of tocolysis. For example, many obstetricians in Europe and even more so in the USA and Canada affirm the use of short-term (< 2 days) tocolysis: 5 -7 a Canadian study found that tocolytics such as ritodrine hydrochloride prolonged the duration of pregnancy up to 2 days, 8 whereas no largescale studies have assessed the clinical efficacy of long-term (> 2 days) tocolysis.
The current multicentre, retrospective study was, therefore, conducted to evaluate whether long-term tocolysis, defined as tocolysis that effectively prolongs gestation > 2 days after treatment initiation, is effective in treating threatened premature labour.
Patients and methods

PATIENTS
With the exception of pregnant women participating in other clinical trials, all pregnant women who had been admitted for the treatment of threatened premature labour between 1 July and 31 December 1998, at 37 hospitals in Japan participating in the Multicentre Premature Labour Study Group, were included in the study. As this was a retrospective study of outcomes, ethics approval and informed consent were deemed to be unnecessary.
DATA COLLECTION
Patient characteristics including age, parity, gestational age, multiple pregnancy, presence of uterine deformity, membrane rupture, presence of intra-uterine infection, vaginitis, hydramnios, uterine contraction, uterine bleeding, cervical cerclage and 'other complications' were recorded on admission. Frequency of uterine contractions, uterine bleeding, membrane rupture and cervical dilatation were recorded. Neonatal outcome including whether alive or dead, neonatal weight, gender and 1-min Apgar score were recorded.
DATA ANALYSIS
The tocolysis regimen for each patient was not identical but was selected by each obstetrician. Thus, patients were stratified into two groups: those treated with tocolytics, and those not treated with tocolytics (unmedicated, bed-rest group). Patients treated with tocolytics were sub-classified into the following four treatment groups: intravenous (IV) ritodrine; IV ritodrine plus oral ritodrine; IV ritodrine plus other drugs; and other drugs. In Japan, ritodrine is the standard tocolytic for treating threatened premature labour and the drugs used for tocolysis in the present study are shown in Table 1 The patients in each group were further stratified into three groups according to the tocolysis index (TI) of Baumgarten and Gruber 9 , in order to assess the efficacy of treatment according to the risk of premature labour. The TI scores of 0 -12 were derived from scores of uterine contraction (none 0, irregular 1 and regular 2), premature rupture of membranes (not ruptured 0, suspected rupture 2 and definite rupture 4), genital bleeding (none 0, spotting 1 and moderate 2) and cervical dilatation (no dilatation 0, 1 cm 1, 2 cm 2, 3 cm 3, 4 cm 4). A TI score ≥ 7 indicated a poor prognosis. 9 The endpoint of gestational duration was set as day 6 of gestation week 35. Those patients who were admitted to hospital before gestation week 32 for the management of pre-term labour and who had TI > 2 were separately divided from all the other patients into two sub-groups based K Takagi, K Satoh Efficacy of long-term tocolysis on TI scores: sub-group A had a TI of 3 -6; sub-group B had a TI ≥ 7. Patients whose uterine contractions were properly controlled or whose gestation was prolonged beyond week 35 were evaluated as having a successful outcome, and the success rate for each group was compared. The number of days that gestation was prolonged was retrospectively calculated using the Kaplan-Meier method in order to estimate the clinical efficacy of tocolysis. Neonatal prognoses and the adverse effects of tocolytic agents were also evaluated.
STATISTICAL ANALYSIS
The Kaplan-Meier method and a log-rank test were used to determine the efficacy of tocolysis. The χ 2 tests and Mann-Whitney Utests were used to assess statistical significance. A P-value ≤ 0.05 was considered to indicate statistical significance.
Results
PATIENTS
The total number of case records collected was 1310 of which 1147 were eligible for analysis. Eight cases were excluded due to duplication and 155 were excluded due to insufficient records. Details of the baseline characteristics of the 1147 analysed cases are given in Table 2 .
TOCOLYSIS OF CHOICE
Tocolytics were used in 1054 (91.9%) of the patients eligible for analysis, as shown in Table 3 which also shows the frequencies of single and multiple drug use. Tocolysis with a single drug was the most frequent (54.6% of cases), followed by two-drug tocolysis (32.1%). Administration of IV ritodrine occurred in 909 (79.3%) patients, in singleor multiple-drug regimens as shown in Table  4 . Drugs other than IV ritodrine were: oral ritodrine following IV therapy (n = 198), magnesium sulphate (n = 228), terbutaline (n = 39), indomethacin (n = 31) and urinastatin (n = 18). The most frequently used combination therapies were ritodrine plus magnesium sulphate (n = 219) and IV plus oral ritodrine (n = 198).
PATIENT CLASSIFICATION FOR ANALYSIS
Since 909 (86.2%) of the patients who underwent tocolysis were treated with IV ritodrine, either as monotherapy, IV plus oral therapy or in combination with other agents (Table 4) , analysis according to risk of premature labour was conducted on these patients. Prolongation of gestation in patients given tocolysis was compared with that for the 93 patients who were only given unmedicated bed-rest. As can be seen in Table 4 , a total of 444 (44.3%) women treated with IV ritodrine or unmedicated were at TI grade ≤ 2; 451 (45.0%) women were between TI grades 3 and 6; and 107 (10.7%) women had TI grades ≥ 7. Patient distribution according to TI grade in the groups treated with IV ritodrine alone or in combination with other tocolytics was comparable. In contrast, differences in the distribution pattern were apparent for patients treated with IV ritodrine and oral ritodrine, with significantly more patients having lower TI scores indicative of a lesssevere risk of pre-term labour (P < 0.01; Table   4 ). For this reason, patients treated with IV ritodrine and oral ritodrine were excluded from the analyses of clinical efficacy.
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CLINICAL OUTCOME
Clinical efficacy by severity and tocolysis
The number of patients in sub-group A (admission before gestation week 32 and TI score 3 -6) totalled 223, consisting of 212 (ritodrine alone and ritodrine + other drugs) and 11 (unmedicated, bed-rest) ( Fig. 1) . Gestation was significantly prolonged in patients who underwent tocolysis treatment compared with the unmedicated bed-rest K Takagi, K Satoh Efficacy of long-term tocolysis group (P < 0.05; Fig. 1 ): ritodrine prolonged gestation significantly longer (5 -26 days) compared with no medication (2 -11 days). In comparison with the unmedicated group, the mean duration of prolongation was 2.2 times longer (P = 1.2 × 10 -8 ; Table 5 ).
Similar results were seen in sub-group B
(admission before gestation week 32 and TI score ≥ 7); the number of patients in subgroup B was 45, consisting of 38 (ritodrine alone and ritodrine + other drugs) and seven (unmedicated, bed-rest) (Fig. 2) . Compared with the unmedicated bed-rest group, patients who underwent tocolysis had a 
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mean prolongation of gestation that was 3.1 times longer (P = 4.5 × 10 -6 ; Table 5 ). A χ 2 analysis was applied in these patients to determine the difference between the number of patients whose gestation was prolonged for > 2 days (from initiation of tocolysis treatment until delivery) and those whose gestation was prolonged for ≤ 2 days (Table 6 ). Analysis showed that the number of patients whose gestation was prolonged for > 2 days in the tocolysis group was significantly greater than in the unmedicated bed-rest group (P = 1.06 × 10 -4 ). Even in the TI ≤ 2 sub-group, where tocolysis might be considered optional, tocolytics significantly prolonged gestation (P = 0.026) in comparison with no medication ( Table 5) .
Efficacy by tocolysis administered
Tocolysis success rates were 65.2% (316/485) in patients who received IV ritodrine alone, 41.6% (94/226) in patients who received IV 
NEONATAL SHORT-TERM OUTCOMES
Data on neonatal outcome (birth weight, mortality and 1-min Apgar score) are shown in Table 7 . The total number of neonates produced by the 1147 analysed cases was 1331 and the mortality rate was 3.3%. The survival rate of neonates delivered at 22 -24 weeks' gestation was 32%, increasing to 75% in neonates delivered at weeks 24 -26 and at weeks 30 -32 was 94% (Fig. 3A) .
There was a positive correlation between birth weight and neonatal survival. The survival rate of newborns with birth weights ≥ 1500 g exceeded 95% and there were no deaths among newborns with birth weights ≥ 2000 g (Fig. 3B) .
No statistically significant differences in neonatal findings for gestation weeks at birth, birth weight, incidence of respiratory distress syndrome (RDS), 1-min Apgar scores, or survival rates were found between patients treated with tocolytics and those untreated.
ADVERSE REACTIONS TO TOCOLYTICS
Maternal adverse reactions to tocolytics were observed in 113 (12.4%) out of 909 ritodrinetreated women. The most frequent adverse reactions were tachycardia and cardiac arrhythmia (n = 45, 5.0%), hepatic disorder (32 cases, 3.5%), tremors (1.5%) and 
Discussion
Threatened premature labour is treated using a variety of tocolytic methods, depending on the diagnostic criteria, the drugs available, and the likely duration and goals of therapy. Furthermore, traditional birth and delivery practices, lifestyles and medical support systems differ from country to country, making it difficult to identify any single global standard.
Pre-term birth rates were reported to be 5.4% in Japan 10 and 5 -7% in Europe in 2000, 11, 12 whereas the pre-term birth rate in the US (defined as delivery prior to week 37 of gestation) was reported to be 12.1% in 2002, a 29% increase over the previous two decades. 13 Most of this increase related to births between 32 and 36 weeks' gestation, whereas the preterm birth rates prior to 32 weeks' gestation 
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remained stable at about 2%. 13 Worldwide, the most commonly used tocolytics were the β 2 stimulants, which include ritodrine and magnesium sulphate. In the USA and Canada, however, it appears that ritodrine is considered to be of limited effectiveness: the general view appears to be that ritodrine is only effective in prolonging pregnancy for a period of 24 -48 h. 8,14 -17 Magnesium sulphate has been associated with insufficient inhibition of uterine contractions and safety concerns. 18, 19 The present study showed that ritodrine therapy maintained pregnancy beyond 35 weeks in women with threatened premature labour with TI ≥ 3, prolonging gestation significantly longer (5 -26 days) compared with the unmedicated bed-rest group (2 -11 days) . Moreover, for patients with TI 3 -6 and TI ≥ 7, prolongation of gestation with ritodrine, was 2.2 and 3.1 times longer, respectively, than with no medication. These results clearly show that treatment of threatened premature labour using ritodrine is effective and useful for long-term tocolysis (defined as tocolysis that prolongs pregnancy > 2 days).
Patients registered in the clinical study reported by the Canadian Preterm Labor Investigators Group 8 included cases with membrane rupture (25% of cases), cervical length shortened by > 50%, and cervical dilation of > 2 cm of which > 10% were > 4 cm dilated. A clinical study by Garite et al. 20 involving cases with membrane rupture showed no significant difference in prolongation of gestation between patients receiving tocolysis with ritodrine and those receiving no medication: 80% of the women gave birth within 24 h of treatment initiation. This indicates that tocolysis using ritodrine may not always be effective in cases with membrane rupture. The reason why the prolongation effects of ritodrine were limited to < 2 days in the Canadian group's clinical trial may be, as suggested by Garite et al., 20 that most of the cases in the Canadian study involved ruptured membranes or a highly dilated cervix, both of which are rather difficult to treat with ritodrine.
The present study analysed the effects of tocolysis with ritodrine on the more severe cases (TI ≥ 7), which included cases of membrane rupture and cervical dilatation > 4 cm. Whereas the Canadian report 8 indicated that tocolytics such as ritodrine extended the duration of pregnancy up to 2 days, the present study showed that, even in the most severe TI ≥ 7 cases, the number of cases in which the duration of pregnancy was prolonged by > 2 days was significantly greater in those treated with ritodrine compared with unmedicated cases. The present study, therefore, supports the view that using tocolytics such as ritodrine for > 2 days, or as long as the pregnancy lasts, is effective and useful for the treatment of threatened premature labour. It also confirms the effectiveness of the long-term tocolysis regimens currently used to treat threatened premature labour in Japan.
A reason why long-term tocolysis is rarely used in the USA may be the high incidence of adverse effects reported with ritodrine (which include nausea, vomiting, tremors and tachycardia). 6, 7, 21 Lung oedema, which is the most severe side-effect of ritodrine, was reported by Leveno and Cunningham. 5 in 3 -9% of cases, and by Higby et al. 22 in approximately 5% of cases. Its pathogenesis may be secondary overhydration caused by both the anti-diuretic activity of high doses of a β 2 stimulant such as ritodrine given concomitantly with a large volume of IV fluids containing β 2 stimulants. 5 In Japan, the maximum dosage for IV ritodrine is strictly limited to 200 µg/min, whereas in the K Takagi, K Satoh Efficacy of long-term tocolysis USA and Canada 350 µg/min is indicated as the maximum dose. This may be another cause of the higher incidence of lung oedema in the treatment of threatened premature labour in the USA 5,22 than in the present study (0.3% 5 vs 0.15%).
The Canadian study reported a high incidence of maternal side-effects with ritodrine including tachycardia (53.4%), nausea (20.5%), tremor (39.2%) and headache (23.0%). 8 A much lower incidence of side-effects was recorded in the present study: tachycardia (4.0%), nausea and vomiting (0.7%) and tremor (1.5%). Differences in the incidence of such sideeffects may be attributable to the Japanese practice of gradually increasing the dose of IV ritodrine for long-term tocolysis, whereas in the USA and Canada the generally accepted practice is to increase the dose up to an effective level as quickly as possible within 2 days. In Japan, treatment is expected to prolong pregnancy as much as possible by suppressing uterine contractions enough to delay delivery but, in the US and Canada, it is used to maintain pregnancy by substantial and rapid inhibition of contractions for a period long enough to enable maturation of the fetal lung to be promoted with corticosteroids. 23 Recent progress in neonatal medicine has brought remarkable improvements in the primary prognosis for premature neonates in Japan. Although 32% survival rates were reported for neonates delivered at 22 -24 weeks' gestation in the present study, rates were increased to 75% for neonates delivered at 24 -26 weeks and to 94% for neonates delivered at 30 -32 weeks. A correlation was also observed between high birth weights and low neonatal death rates: survival was > 95% for neonates weighing ≥ 1500 g and no deaths were recorded for neonates weighing ≥ 2000 g.
Pre-term infants are also prone to physical and mental disorders such as RDS, intraventricular haemorrhage, cerebral palsy, mental retardation and prematurityinduced retinopathy, for which a correlation with gestation weeks and birth weight has been reported. 24 Tsuneishi et al. 24 reported on extremely low birth-weight infants who had cerebral palsy (5.8%), mental retardation (9.7%) or both (7.7%) at 6 years of age. Hack et al. 25 reported that, among infants with birth weights < 750 g, mental retardation was observed in 21% and cerebral palsy in 9% when they reached the lower grades of primary school. Johnson et al. 26 also showed that half of all infants born prior to the 29th week of gestation had moderate to severe physical disorders at 4 years of age.
Prolonging the duration of pregnancy by long-term tocolysis, as reported in the present study, and the consequential improvement in survival rates for premature newborns may lead to overall reductions in medical costs. A recent survey showed that medical care expenses for infants born at 38 weeks' gestation were 10% of those for infants born at 35 weeks (US$441 versus US$4733). 27 Rolnick et al. 28 reported that medical expenses to treat low birth-weight infants (1500 -2499 g) during the first post-natal year were 46% higher than those for normal birth-weight infants. According to a report by Ibara and Ikenoue 29 in Japan, the more that a pregnancy is prolonged, the greater the reduction in neonatal medical expenses from birth to discharge, especially for preterm births. Prolonging pregnancy by a single week can greatly reduce the expenses incurred in treating premature infants who would have been born at earlier stages of gestation. 29 If pregnancy is prolonged from 24 to 25 weeks, for • Received for publication 20 July 2008 • Accepted subject to revision 1 August 2008
• Revised accepted 2 December 2008 Copyright © 2009 Field House Publishing LLP example, expenses can be reduced by up to US$14 600 (¥1 600 000) and, if pregnancy is prolonged from 30 to 31 weeks, expenses can be reduced by up to US$4600 (¥500 000). 29 The significance of treating threatened premature labour therefore needs to be considered from an economic, as well as a medical, standpoint.
